Aldeyra Therapeutics to seek FDA dispute review for reproxalap
The company said it plans to submit a Formal Dispute Resolution Request to the FDA over reproxalap for dry eye disease. Aldeyra also said it now expects operational cash runway into 2029 based on reported cash and cash equivalents of $45.1 million as of June 30, 2026.